

  
**TIAAN**  
AYURVEDIC & HERBS LIMITED  
(Formerly known as Rachana Capital & Securities Ltd)

29.05.2019

To,  
BSE Ltd.  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai-400 001

**Scrip Code: 540108**  
**Scrip Symbol: TAHL**

**Sub: Outcome of Board Meeting**

Dear Sir,

The Board of Directors of the Company at its meeting held on 29<sup>th</sup> May, 2019 inter alia has transacted, adopted and approved the Following:

- 1) The Standalone Audited Financial Results for the Quarter and Year ended 31<sup>st</sup> March, 2019 as per Regulation 33 of SEBI (LODR) Regulation, 2015 with Auditors Report of Statutory Auditors of the Company.

The Meeting of Board of Directors of the Company commenced from 07:50 p.m. and closed at 8:50 p.m.

Kindly take note of the above and oblige.

By order of the Board

For Tiaan Ayurvedic & Herbs Limited



**Mr. Maz Shaikh**  
Executive Director  
(DIN: 08248302)

Registered office: 405, Patel Ashwamegh Complex, Jetalpur Road, Near Dairy Den Circle, Sayajigunj, Vadodara, Gujarat- 390005

☎ 063590 93939

Corporate office: Crystal Plaza, 610- A-Wing, Opp. Infinity Mall, Link Road, Andheri (West), Mumbai- 400053. ☎ 98333 19639

✉ rachnacapital@gmail.com | 🌐 www.tiaanonline.com

CIN No.: L85100GJ1992PLC017397

**Statement of Audited Financial Results for the Quarter & Year ended 31<sup>st</sup> March, 2019**

Particulars	Quarter Ended			For the year ended	
	31/03/2019	31/12/2018	31/03/2018	31/03/2019	31/03/2018
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I. Revenue from operations	253,656,555	114,583,381	332,55,550	488,616,424	101,522,940
II. Other income	3,247	230,268	158,009	326,965	649,074
<b>III. Total Revenue (I + II)</b>	<b>253,659,802</b>	<b>114,813,649</b>	<b>33,413,559</b>	<b>488,943,389</b>	<b>102,172,014</b>
<b>IV. Expenses:</b>					
Cost of materials consumed	0	0	0	0	0
Purchases of Stock-in-Trade	243,558,090	103,332,284	305,95,106	453,820,510	93,392,659
Changes in inventories of finished goods work-in-progress and Stock-in-Trade	0	0	0	0	0
Employee benefits expense	836,880	1,180,845	836,880	3,972,475	2,175,584
Finance Costs	0	0	0	0	0
Depreciation and amortisation expense	556,973	1,355,384	212,526	2,210,895	680,083
Other expenses	2,005,377	1,525,720	395,677	5,665,560	1,660,264
<b>Total expenses</b>	<b>246,957,320</b>	<b>107,394,233</b>	<b>32,040,189</b>	<b>465,669,440</b>	<b>97,908,590</b>
<b>V. Profit before exceptional items and tax (III - IV)</b>	<b>6,702,482</b>	<b>7,419,416</b>	<b>13,73,370</b>	<b>23,273,949</b>	<b>4,263,424</b>
VI. Exceptional items	0	0	0	0	0
<b>VII. Profit before Tax (V - VI)</b>	<b>6,702,482</b>	<b>7,419,416</b>	<b>13,73,370</b>	<b>23,273,949</b>	<b>4,263,424</b>
<b>VIII. Tax expense:</b>					
(1) Current tax	1,675,620	1,619,631	390,100	5,818,487	1,236,892
(2) Deferred tax	0	0	0	0	0
<b>IX. Profit(Loss)for the period from continuing operations(VII-VIII)</b>	<b>5,026,861</b>	<b>5,799,785</b>	<b>983,270</b>	<b>17,455,462</b>	<b>3,026,532</b>
X. Profit/(loss) from discontinuing operations	0	0	0	0	0
XI. Tax expense of discontinuing operations	0	0	0	0	0
<b>XII. Profit/(loss) from Discontinuing operations (after tax)(X-XI)</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>XIII. Profit (Loss) for the period (IX+XII)</b>	<b>5,026,861</b>	<b>5,799,785</b>	<b>983,270</b>	<b>17,455,462</b>	<b>3,026,532</b>
<b>XIV. Other Comprehensive Income</b>					
A. (i) Items that will not be reclassified to profit or loss	0	0	0	0	0
(ii) Income tax relating to items that will not be reclassified to profit or loss	0	0	0	0	0
B. (i) Items that will be reclassified to profit or loss	0	0	0	0	0
(ii) Income tax relating to items that will be reclassified to profit or loss	0	0	0	0	0
<b>XV. Total Comprehensive Income for the period (XIII+XIV) Comprising profit(loss) and other comprehensive Income for the period)</b>	<b>5,026,861</b>	<b>5,799,785</b>	<b>983,270</b>	<b>17,455,462</b>	<b>3,026,532</b>
<b>Paid up Equity Share Capital</b>	<b>51,668,000</b>	<b>51,668,000</b>	<b>51,668,000</b>	<b>51,668,000</b>	<b>31,038,000</b>
<b>XVI. Earnings per equity share:</b>					
(1) Basic	0.973	1.122	0.19	3.37	0.975
(2) Diluted	0.973	1.122	0.19	3.37	0.975



**Notes:**

1. The Standalone Financial Results of the Company for the Quarter and Year ended on 31<sup>st</sup> March, 2019 have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 29<sup>th</sup> May, 2019.
2. The Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
3. Figures of the Quarter ended 31<sup>st</sup> March, 2019 and 31<sup>st</sup> March, 2018 are the balancing figures between the audited figures in respect of the full financial year and the reviewed figures up to the third quarter of the relevant financial year.
4. Previous year/period figures have been regrouped/rearranged wherever necessary to make them Comparable with current period figures.
5. The Company has only One Reportable Segment i.e. Ayurvedic & Herbs Product.

Date: 29.05.2019  
Place: Vadodara

 For Trian Ayurvedic & Herbs Limited  
  
Inteyaz Shaikh  
Executive Director  
(DIN: 08248302)

STATEMENT OF ASSETS AND LIABILITIES		
PARTICULARS	AS AT 31-03-19 (AUDITED)	AS AT 31-03-18 (AUDITED)
<b>ASSETS</b>		
<b>Non-Current Assets</b>		
(a) Property, Plant, Equipment	11,025,654	7,728,869
(b) Capital Work-in-progress	0	0
(C) Investment	0	0
(d) Goodwill	0	0
(e) Other Intangible Assets	0	0
<b>Non-Current Financial Assets</b>		
(f) Non-Current Investments	7,500,000	7,500,000
(g) Trade Receivables	0	0
(h) Loans	7,521,000	6,500,000
(i) Deferred Tax Assets (Net)	0	0
(j) Other Non-Current Assets	0	0
<b>Total Non-Current Assets</b>	<b>26,046,654</b>	<b>21,728,869</b>
<b>Current Assets</b>		
(a) Inventory	21,548,561	0
(b) Financial Assets	0	0
(i) Investment	0	0
(ii) Trade Receivables	125,117,152	22,060,038
(iii) Cash and Cash equivalents	277,465	227,248
(iv) Loans	0	0
(v) Other Financial Assets	0	0
(c) Other Current Assets	1,123,715	4,232,520
<b>Total Current Assets</b>	<b>148,066,893</b>	<b>26,519,806</b>
<b>Total Assets</b>	<b>174,113,547</b>	<b>48,248,675</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share Capital	51,668,000	31,038,000
(b) Reserves	19,840,388	2,384,926
<b>Total Equity</b>	<b>71,508,388</b>	<b>33,422,926</b>
<b>Liabilities</b>		
<b>Non-Current Liabilities</b>		
(a) Borrowings	0	0
(b) Deferred Tax Liabilities (net)	0	0
(c) Trade Payables	95,478,923	13,308,324
(d) Provisions	6,250,780	1,413,223
(e) Other Current Liabilities	875,456	104,202
<b>Total Current Liabilities</b>	<b>102,605,159</b>	<b>14,825,749</b>
<b>Total Equity and Liabilities</b>	<b>174,113,547</b>	<b>48,248,675</b>

Date: 29.05.2019  
Place: Vadodara



For Tiaan Ayurvedic & Herbs Limited

Inteyaz Shaikh  
Executive Director  
(DIN: 08248302)



**Auditor's Report On Quarterly Standalone Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.**

To  
**Board of Directors of  
Tiaan Ayurvedic & Herbs Limited**

We have audited the Quarterly Standalone Financial Results of Tiaan Ayurvedic & Herbs Limited ("the Company"), for the quarter ended 31<sup>st</sup> March, 2019 and the year to date results for the period 1<sup>st</sup> April, 2018 to 31<sup>st</sup> March, 2019, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard: and
- ii. give a true and fair view of the net profit and other financial information for the quarter ended 31<sup>st</sup> March, 2019 as well as the year to date results for the period from 1<sup>st</sup> April, 2018 to 31<sup>st</sup> March, 2019.

For MEHUL M SHAH & CO.  
CHARTERED ACCOUNTANTS  
FRN.141907W

(MEHUL SHAH)  
PROPERITOR  
Membership No.044044  
Date.29/05/2019

